These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1889632)

  • 1. Regulatory implications: an authority's perspective.
    Cartwright AC
    Biochem Soc Trans; 1991 Apr; 19(2):465-7. PubMed ID: 1889632
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulatory implications: a committee member's perspective.
    Brown JR
    Biochem Soc Trans; 1991 Apr; 19(2):463-5. PubMed ID: 1889631
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulatory implications: a company's perspective.
    Macdonald CM
    Biochem Soc Trans; 1991 Apr; 19(2):467-8. PubMed ID: 1889633
    [No Abstract]   [Full Text] [Related]  

  • 4. Assessing atropisomer axial chirality in drug discovery and development.
    Laplante SR; D Fader L; Fandrick KR; Fandrick DR; Hucke O; Kemper R; Miller SP; Edwards PJ
    J Med Chem; 2011 Oct; 54(20):7005-22. PubMed ID: 21848318
    [No Abstract]   [Full Text] [Related]  

  • 5. A patent lawyer's perspective.
    White AW
    Biochem Soc Trans; 1991 Apr; 19(2):469-72. PubMed ID: 1889634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inspections: the international regulatory view.
    Turner JL
    PDA J Pharm Sci Technol; 1994; 48(4):180-1. PubMed ID: 7804815
    [No Abstract]   [Full Text] [Related]  

  • 7. Chirality and its importance in drug development.
    Campbell DB; Wilson K
    Biochem Soc Trans; 1991 Apr; 19(2):472-5. PubMed ID: 1889635
    [No Abstract]   [Full Text] [Related]  

  • 8. Present attitudes of governmental drug regulatory agencies.
    Noel PR
    Int J Clin Pharmacol; 1973 Apr; 7(2):168-77. PubMed ID: 4731283
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA, states discuss pharmacy compounding regulatory framework.
    Traynor K
    Am J Health Syst Pharm; 2013 Feb; 70(3):180, 182. PubMed ID: 23327976
    [No Abstract]   [Full Text] [Related]  

  • 10. Availability of medicines.
    Swarbrick O
    Vet Rec; 1992 May; 130(19):431. PubMed ID: 1307856
    [No Abstract]   [Full Text] [Related]  

  • 11. Availability of medicines.
    Armour J
    Vet Rec; 1992 Jun; 130(23):519. PubMed ID: 1641971
    [No Abstract]   [Full Text] [Related]  

  • 12. Legislation on medicines.
    Dunlop D
    Br Med J; 1970 Sep; 3(5725):760-2. PubMed ID: 5472762
    [No Abstract]   [Full Text] [Related]  

  • 13. Is the Hospital Authority's drug formulary equitable and efficient?
    Lau EW; Leung GM
    Hong Kong Med J; 2008 Oct; 14(5):416-7. PubMed ID: 18840919
    [No Abstract]   [Full Text] [Related]  

  • 14. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective.
    Chen ML
    Adv Drug Deliv Rev; 2008 Mar; 60(6):768-77. PubMed ID: 18077051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3. Drug regulations in Switzerland and their application.
    Hippenmeier F
    Bull Parenter Drug Assoc; 1974; 28(4):167-73. PubMed ID: 4855448
    [No Abstract]   [Full Text] [Related]  

  • 16. Availability of medicines.
    Rutter JM
    Vet Rec; 1992 May; 130(21):478. PubMed ID: 1626359
    [No Abstract]   [Full Text] [Related]  

  • 17. POM explained.
    Br J Hosp Med; 1978 Mar; 19(3):198. PubMed ID: 630163
    [No Abstract]   [Full Text] [Related]  

  • 18. When is a derivative not a derivative?
    Phillips GF
    Med Sci Law; 1973 Jul; 13(3):216-20. PubMed ID: 4729113
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug licensing or innovation.
    Lancet; 1981 Oct; 2(8250):788. PubMed ID: 6116910
    [No Abstract]   [Full Text] [Related]  

  • 20. Overhauling oversight--European drug legislation.
    Tsang L
    Nat Biotechnol; 2005 Sep; 23(9):1050-3. PubMed ID: 16151389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.